FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884134518> ?p ?o ?g. }

• W2884134518 endingPage "233" @default.
• W2884134518 startingPage "227" @default.
• W2884134518 abstract "Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) detects prostate cancer recurrence at low PSA levels. Radiotherapy with dose escalation to the former prostate bed has been associated with improved biochemical recurrence-free survival (BRFS). Thus, we hypothesized that PSMA PET/CT-guided salvage radiotherapy leads to improved BRFS. Methods: A total of 204 consecutive patients were referred for salvage radiotherapy following radical prostatectomy. PSMA PET/CT scans were performed and patients with PSA persistence (109 patients) or evidence of distant metastases (5 patients) were excluded from this analysis. Thus, the following analysis is based on a total of 90 patients who underwent PSMA PET/CT prior to radiotherapy due to biochemical recurrence and received salvage radiotherapy. In case of PET-positive findings, antiandrogen therapy was commenced before initiation of radiotherapy. BRFS (PSA ≤ 0.2 ng/ml) was defined as the study endpoint. Results: PET-positive lesions were detected in 42/90 (47%) patients: 24/42 (27%) fossa recurrence only, 12/42 (13%) pelvic lymph nodes only and 6/42 (7%) fossa and pelvic lymph node recurrence. Median PSA before radiotherapy was 0.44 (0.11 - 6.24). Cumulatively, a total dose of 70.0 Gy (67.2 - 72 Gy) was delivered to local macroscopic tumor, 66 Gy (59.4 - 70.2 Gy) to the prostatic fossa, 60.8 Gy (54 - 66 Gy) to PET-positive lymph nodes and 50.4 Gy (45 - 50.4 Gy) to the lymphatic pathways. After a median follow-up of 23 months, BRFS was 78%. Antiandrogen therapy was ongoing in 4 patients at last follow-up. No significant difference in BRFS between PET-positive (74%) vs. PET-negative patients (82%; p>0.05) was observed at last follow-up. Two patients had late genitourinary toxicity grade 3 and no patient had gastrointestinal toxicity ≥ 3 (NCI-CTCAE v4.03). Conclusion: PSMA PET/CT-guided salvage radiotherapy is an effective and safe local treatment option. No difference in BRFS between PET-positive and PET-negative patients was observed, indicating effective targeting of PET-positive lesions. PSMA PET/CT when readily available should be offered to patients with PSA recurrence for treatment individualization." @default.
• W2884134518 created "2018-08-03" @default.
• W2884134518 creator A5004272744 @default.
• W2884134518 creator A5012670084 @default.
• W2884134518 creator A5017268914 @default.
• W2884134518 creator A5020162911 @default.
• W2884134518 creator A5022823820 @default.
• W2884134518 creator A5037412930 @default.
• W2884134518 creator A5038323479 @default.
• W2884134518 creator A5039176724 @default.
• W2884134518 creator A5043313789 @default.
• W2884134518 creator A5045885487 @default.
• W2884134518 creator A5051667568 @default.
• W2884134518 creator A5052937691 @default.
• W2884134518 creator A5062907808 @default.
• W2884134518 creator A5066330818 @default.
• W2884134518 creator A5078191247 @default.
• W2884134518 creator A5085968028 @default.
• W2884134518 date "2018-07-12" @default.
• W2884134518 modified "2023-10-16" @default.
• W2884134518 title "Outcome After PSMA PET/CT–Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis" @default.
• W2884134518 cites W1772827770 @default.
• W2884134518 cites W1965408806 @default.
• W2884134518 cites W1968170734 @default.
• W2884134518 cites W1994260842 @default.
• W2884134518 cites W2004229786 @default.
• W2884134518 cites W2034596541 @default.
• W2884134518 cites W2035259525 @default.
• W2884134518 cites W2116952544 @default.
• W2884134518 cites W2137491531 @default.
• W2884134518 cites W2137670219 @default.
• W2884134518 cites W2151660174 @default.
• W2884134518 cites W2155847415 @default.
• W2884134518 cites W2181191878 @default.
• W2884134518 cites W2217765345 @default.
• W2884134518 cites W2281201358 @default.
• W2884134518 cites W2326657743 @default.
• W2884134518 cites W2406375637 @default.
• W2884134518 cites W2487033212 @default.
• W2884134518 cites W2510755861 @default.
• W2884134518 cites W2517713070 @default.
• W2884134518 cites W2540348172 @default.
• W2884134518 cites W2552100324 @default.
• W2884134518 cites W2561039633 @default.
• W2884134518 cites W2585109238 @default.
• W2884134518 cites W2591849683 @default.
• W2884134518 cites W2592014261 @default.
• W2884134518 cites W2604330013 @default.
• W2884134518 cites W2610570185 @default.
• W2884134518 cites W2615655377 @default.
• W2884134518 cites W2673309218 @default.
• W2884134518 cites W2737584987 @default.
• W2884134518 cites W2746662560 @default.
• W2884134518 cites W2747812764 @default.
• W2884134518 cites W2767882393 @default.
• W2884134518 cites W2774325924 @default.
• W2884134518 cites W4242531351 @default.
• W2884134518 cites W4291982393 @default.
• W2884134518 cites W4295773257 @default.
• W2884134518 doi "https://doi.org/10.2967/jnumed.118.212563" @default.
• W2884134518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30002108" @default.
• W2884134518 hasPublicationYear "2018" @default.
• W2884134518 type Work @default.
• W2884134518 sameAs 2884134518 @default.
• W2884134518 citedByCount "55" @default.
• W2884134518 countsByYear W28841345182018 @default.
• W2884134518 countsByYear W28841345182019 @default.
• W2884134518 countsByYear W28841345182020 @default.
• W2884134518 countsByYear W28841345182021 @default.
• W2884134518 countsByYear W28841345182022 @default.
• W2884134518 countsByYear W28841345182023 @default.
• W2884134518 crossrefType "journal-article" @default.
• W2884134518 hasAuthorship W2884134518A5004272744 @default.
• W2884134518 hasAuthorship W2884134518A5012670084 @default.
• W2884134518 hasAuthorship W2884134518A5017268914 @default.
• W2884134518 hasAuthorship W2884134518A5020162911 @default.
• W2884134518 hasAuthorship W2884134518A5022823820 @default.
• W2884134518 hasAuthorship W2884134518A5037412930 @default.
• W2884134518 hasAuthorship W2884134518A5038323479 @default.
• W2884134518 hasAuthorship W2884134518A5039176724 @default.
• W2884134518 hasAuthorship W2884134518A5043313789 @default.
• W2884134518 hasAuthorship W2884134518A5045885487 @default.
• W2884134518 hasAuthorship W2884134518A5051667568 @default.
• W2884134518 hasAuthorship W2884134518A5052937691 @default.
• W2884134518 hasAuthorship W2884134518A5062907808 @default.
• W2884134518 hasAuthorship W2884134518A5066330818 @default.
• W2884134518 hasAuthorship W2884134518A5078191247 @default.
• W2884134518 hasAuthorship W2884134518A5085968028 @default.
• W2884134518 hasBestOaLocation W28841345181 @default.
• W2884134518 hasConcept C121608353 @default.
• W2884134518 hasConcept C126322002 @default.
• W2884134518 hasConcept C126838900 @default.
• W2884134518 hasConcept C126894567 @default.
• W2884134518 hasConcept C141071460 @default.
• W2884134518 hasConcept C2775842073 @default.
• W2884134518 hasConcept C2776694085 @default.
• W2884134518 hasConcept C2777008409 @default.
• W2884134518 hasConcept C2779466945 @default.

• next